Elunetirom shows synaptogenic promise as Autobahn eyes pivotal trials in depression
Autobahn’s elunetirom may offer a novel neuroplasticity-driven treatment for depression. Find out what its latest data mean for the future of MDD therapy.
Pharma & Biotech